Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020

March 2020 | 300 pages | ID: E74805AE443EN
Global Markets Direct

Abstracts

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 8, 54, 21 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 13 and 7 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AIM ImmunoTech Inc, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes Inc, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AntoXa Corp, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arisan Therapeutics Inc, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H1 2020 (Contd..3), H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H1 2020 (Contd..4), H1 2020
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Abivax SA
AIM ImmunoTech Inc
Akshaya Bio Inc
AnGes Inc
ANP Technologies Inc
AntoXa Corp
Arisan Therapeutics Inc
Atreca Inc
Avipero Ltd
Beijing Mabworks Biotech Co Ltd
Bharat Biotech Ltd
BioComo Inc
BioCryst Pharmaceuticals Inc
BioFactura Inc
Biotron Ltd
Celdara Medical LLC
Chicago Biosolutions Inc
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Etubics Corp
Fab’entech SA
Fibreu Ltd
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
Galactica Biotech Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
GeoVax Labs Inc
Gilead Sciences Inc
Global BioLife Inc Ltd
Greffex Inc
H&P Labs Inc
Humabs BioMed SA
IDBiologics Inc
ImmuneMed Inc
Immunomodulation Inc
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
Johnson & Johnson
Mapp Biopharmaceutical Inc
Microbiotix Inc
Micropharm Ltd
Novavax Inc
Oncologie Inc
OyaGen Inc
Palisades Therapeutics
PanThera Biopharma LLC
Phelix Therapeutics LLC
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Public Health Vaccines LLC
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Riboscience LLC
Ridgeback Biotherapeutics LP
Rodos BioTarget GmbH
SAB Biotherapeutics Inc
Secarna Pharmaceuticals GmbH & Co. KG
Soligenix Inc
Tamir Biotechnology Inc
Tiba Biotech LLC
Vaccibody AS
Vaxeal Holding SA
XBiotech Inc
Xenothera SAS
Yisheng Biopharma Co Ltd
Zalgen Labs LLC